Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Feature|Articles|October 1, 2026
Q4 2026 Oncology Outlook: Key FDA Decisions to Watch
Author(s)Targeted Oncology Staff
Fact checked by: Andrea Eleazar, MHS, Kelly King
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Advertisement
Advertisement
The final quarter of 2026 is expected to bring several consequential FDA decisions in oncology, spanning targeted therapies, antibody-based treatments, and chimeric antigen receptor (CAR) T-cell therapy. The applications cover a broad range of disease settings, from rare tumors such as tenosynovial giant cell tumors (TGCTs) and gastrointestinal stromal tumors (GISTs) to biomarker-defined populations in lung, breast, and prostate cancers. Several decisions could also introduce therapies earlier in the treatment course or add new options for patients with limited treatment options after disease progression.
Related to this article
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
ASH updates myelofibrosis care with expanded molecular testing, earlier transplant consultation, tailored JAK inhibitor use, anemia strategies, and aspirin guidance to reduce clot risk.
Advertisement
Advertisement